Michael P. Bailey, senior vice president of commercial operations at ImClone Systems, has resigned effective August 1, 2008. Mr. Bailey has accepted a senior level commercial position with Synta Pharmaceuticals, a New England-based biopharmaceutical company.
   
ImClone has appointed Joseph I. DePinto as vice president of commercial operations, effective July 14, 2008. He will assume responsibility for the company's commercial operations department upon Mr. Bailey’s departure. Mr. DePinto has 20 years of experience in pharmaceutical sales, marketing and commercial business strategy for oncology products.
   
“Joe has a solid track record of delivering impressive results for the oncology therapeutic franchises he championed. His proven leadership in sales and marketing will be of significant value as we aggressively seek to maximize the global potential of Erbitux and our robust pipeline of novel antibodies in the future,” said John H. Johnson, chief executive officer of ImClone. “Through Michael’s leadership of ImClone’s commercial efforts over the past two years, we are well positioned to extend the growth of Erbitux in the years to come. We thank Michael and wish him continued success as he pursues the next phase of his career.”
  
Mr. DePinto joins the company from Johnson & Johnson Pharmaceutical Services, where he served as global marketing leader, Oncology Therapeutics since 2006. In this role, he was responsible for leading the development and execution of worldwide commercial strategies, market analyses and forecasts. Previously, Mr. DePinto was with Ortho Biotech Products for 12 years where he held management positions of increasing responsibility in oncology sales and marketing and most recently served as vice president, oncology sales. Prior to joining Ortho Biotech, he held field sales positions at Upjohn Pharmaceuticals from 1990 to 1994.  

News from our sister sites